Skip to main content
. Author manuscript; available in PMC: 2023 Feb 17.
Published in final edited form as: Cell Chem Biol. 2021 Aug 9;29(2):239–248.e4. doi: 10.1016/j.chembiol.2021.07.014

Figure 2: RT-qPCR demonstrating that T3 and thyromimetics regulate TREM2 expression in vitro and in vivo.

Figure 2:

TR agonists T3 (10 nM) and sobetirome (1 μM) upregulate Trem2 in mouse (a) and human (b) primary microglia, (c) mouse macrophage cell line RAW 264.7, (d) hypothyroid mouse whole brain extract (3.05 μmol/kg T3 and 30.5 μmol/kg Sob-AM2), and alter the transcript levels of TREM2 pathway-connected genes by upregulating (e) Cd68 and downregulating (f) Il1b in mouse primary microglia (n = 3–5 as denoted). In contrast, TR antagonist NH-3 (2 μM NH-3 with 10 nM T3) downregulated Trem2 (a) and Cd68 (e) in mouse primary microglia. Statistical significance was determined by a 2-tailed, unpaired t test for comparisons between vehicle and group then were plotted together. Asterisks represent significant difference from vehicle unless otherwise noted (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). All graphs show mean ± SEM.